Atovaquone-proguanil for prophylaxis and treatment of malaria

Annals of Pharmacotherapy

Volumn 37, Issue 9, 2003, Pages 1266-1275

  Marra, Fawziah ^a,b   Salzman, James R ^a,c   Ensom, Mary H H ^a,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c VANCOUVER COASTAL HEALTH   (Canada)

^d CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Antimalarial drugs; Atovaquone proguanil; Malaria

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISIN DERIVATIVE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CYCLOGUANIL; FANSIDAR; HALOFANTRINE; MEFLOQUINE; PLACEBO; PROGUANIL; PYRIMETHAMINE; QUININE; TETRACYCLINE; TETRACYCLINE DERIVATIVE;

ABDOMINAL PAIN; ANOREXIA; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; GASTRITIS; HEADACHE; HEPATOSPLENOMEGALY; HUMAN; LIVER TOXICITY; MALARIA; MALARIA CONTROL; NAUSEA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PRURITUS; REVIEW; SEX DIFFERENCE; TRAVEL; TREATMENT OUTCOME; VERTIGO; VOMITING;

ANTIMALARIALS; ATOVAQUONE; CHLOROGUANIDE; CLINICAL TRIALS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MALARIA, FALCIPARUM; NAPHTHOQUINONES;

EID: 0042424749     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C473     Document Type: Review

References (40)

1. Schwartlander B. Global burden of disease. Lancet 1997;350:141-2.
2. Snow RW, Trape JF, Marsh K. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol 2001;17:593-7.
3. Snow RW, Craig M, Deichmann U, Marsh K. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bull World Health Org 1999;77:624-40.
4. Phillips RS. Current status of malaria and potential for control. Clin Microbiol Rev 2001;14:208-16.
5. Package insert. Malarone (atovaquone and proguanil hydrochloride). Research Triangle Park, NC: GlaxoSmithKline, August 2002.
6. Sun IL, Sun EE, Crane FL, Morre DJ, Lindgren A, Low H. Requirement for coenzyme Q in plasma membrane electron transport. Proc Natl Acad Sci USA 1992;89:11126-30.
7. Fry M, Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 1992;43:1545-53.
8. Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 1999;43:1334-9.
9. Hammond DJ, Burchell JR, Pudney M. Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. Mol Biochem Parasitol 1985;14:97-109.
10. Atovaquone/proguanil (Malarone) for malaria. Med Lett Drugs Ther 2000;42:109-11.
11. Sabchareon A, Attanath P, Phanuaksook P, Chanthavanich P, Poonpanich Y, Mookmanee D, et al. Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 1998;92:201-6.
12. Thapar MM, Ashton M, Lindegardh N, Bergqvist Y, Nivelius S, Johansson I, et al. Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol 2002;58:19-27.
13. Gillotin C, Mamet JP, Veronese L. Lack of a pharmacokinetic interaction between atovaquone and proguanil. Eur J Clin Pharmacol 1999;55:311-5.
14. Edstein MD, Looareesuwan S, Viravan C, Kyle DE. Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone. Southeast Asian J Trop Med Public Health 1996;27:216-20.
15. Hussein Z, Eaves J, Hutchinson DB, Canfield CJ. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin Pharmacol Ther 1997;61:518-30.
16. Hussein Z, Eaves CJ, Hutchinson DB, Canfield CJ. Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. Br J Clin Pharmacol 1996;42:589-97.
17. van Vugt M, Edstein MD, Proux S, Lay K, Ooh M, Looareesuwan S, et al. Absence of an interaction between artesunate and atovaquone-proguanil. Eur J Clin Pharmacol 1999;55:469-74.
18. Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet 2001;40:343-73.
19. Radloff PD, Philipps J, Nkeyi M, Hutchinson D, Kremsner PG. Atovaquone and proguanil for Plasmodimn falciparum malaria. Lancet 1996;347:1511-4.
20. de Alencar FE, Cerutti C Jr, Durlacher RR, Boulos M, Alves FP, Milhous W. et al. Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis 1997;175:1544-7.
21. Looareesuwan S, Wilairatana P, Chalermarut K, Rattanapong Y, Canfield CJ, Hutchinson DB. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 1999;60:526-32.
22. Mulenga M, Sukwa TY. Canfield CJ, Hutchinson DB. Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia. Clin Ther 1999;21:841-52.
23. Anabwani G, Canfield CJ, Hutchinson DB. Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children. Pediatr Infect Dis J 1999;18:456-61.
24. Bustos DG, Canfield CJ, Canete-Miguel E, Hutchinson DB. Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. J Infect Dis 1999;179:1587-90.
25. Bouchaud O, Monlun E, Muanza K, Fontanet A, Scott T, Goetschel A, et al. Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: a randomized comparative trial. Am J Trop Med Hyg 2000;63:274-9.
26. Llanos-Cuentas A, Campos P, Clendenes M, Canfield CJ, Hutchinson DB. Atovaquone and proguanil hydrochloride compared with chloroquine or pyrimethamine/sulfodaxine for treatment of acute Plasmodium falciparum malaria in Peru. Braz J Infect Dis 2001;5:67-72.
27. Looareesuwan S, Wilairatana P, Glanarongran R, Indravijit KA, Supeeranontha L, Chinnapha S, et al. Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Trans R Soc Trop Med Hyg 1999;93:637-40.
28. Berman JD, Nielsen R, Chulay JD, et al. Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. Trans R Soc Trop Med Hyg 2001;95:429-32.
29. Shanks GD, Gordon DM, Klotz FW, Aleman GM, Oloo AJ, Sadie D, et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 1998;27:494-9.
30. Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998;351:709-13.
31. Sukwa TY, Mulenga M, Chisdaka N, Roskell NS, Scott TR. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999;60:521-5.
32. Hogh B, Clarke PD, Camus D, Nothdurft HD, Overbosch D, Gunther M, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. Lancet 2000;356:1888-94.
33. Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001;33:1015-21.
34. Ling J, Baird JK, Fryauff DJ, Sismadi P, Bangs MJ, Lacy M, et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis 2002;35:825-33.
35. Canadian recommendations for the prevention and treatment of malaria among international travellers. Can Commun Dis Rep 2000;26S2:1-42.
36. Health information for international travel 2001-2002. Atlanta: Centers for Disease Control and Prevention, 2001.
37. International travel and health. Geneva: World Health Organization, 2002.
38. Nosten F, Brasseur P. Combination therapy for malaria. The way forward. Drugs 2002;62:1315-29.
39. Lobel HO, Phillips-Howard PA, Brandling-Bennett AD, Steffen R, Campbell CC, Huong AY, et al. Malaria incidence and prevention among European and North American travelers to Kenya. Bull World Health Org 1990;68:209-15.
40. Steffen R. Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy. Bull World Health Org 1990;68:313-22.